The US Supreme Court denied certiorari Monday to pharmaceutical giant Bayer and agrochemical subsidiary Monsanto for the second time this year. Bayer has been seeking certiorari for one of many cases surrounding Roundup, a weed killer produced by Monsanto with alleged cancer-causing properties.

The case in question, Pilliods v. Monsanto, revolves around a California couple who claim Roundup’s key ingredient, glyphosate, caused both of their non-Hodgkin’s lymphoma diagnoses. The California Appeals court held in the couple’s favor, ordering Bayer and Monsanto to pay $86 million in damages (both punitive and compensatory).

Bayer’s five-point plan for managing the current Roundup legal crisis is built around being heard before the Supreme Court, creating a comprehensive claims program, managing the current cases, introducing a new roundup formulation, and their safety study website. Earlier this year on June 21st, Bayer attempted to gain certiorari for a related case, Hardeman v. Monsanto, but was also denied.

Bayer’s spokesperson said in a statement to news outlets that the company “continues to stand fully behind its Roundup,” and “will only consider resolving outstanding current cases and claims if it is strategically advantageous to do so.”

Information on glyphosate’s safety is mixed, with some studies indicating it is safe when used properly and others labeling it a carcinogen.